Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed

Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough data to answer this question. That’s why the GENAYA project was launched in 2022. Through GENAYA, we are analyzing the tumor DNA of a total of 1,000 young cancer patients. As of July 2025, we’ve completed our 500th analysis.
With patient consent, we store the results in a large database that also contains data from over 7,000 other patients. This allows researchers worldwide to compare the data and investigate whether—and how—the DNA of cancer in young people differs from that in older adults, and whether this could lead to more targeted treatments specifically for young patients.
Funding
This project is made possible through funding from the Dutch Cancer Society (KWF Kankerbestrijding) and Fight Cancer Foundation. Illumina is also contributing to the project. Thanks to their support, more research can be conducted, and young cancer patients can receive comprehensive DNA analysis to determine whether there are any leads for targeted (clinical trial) treatments.
GENAYA Project
The GENAYA project (a national database of GENome data of Adolescent and Young Adult cancers) builds on the previously funded COMPRAYA infrastructure, which was also supported by KWF. For GENAYA, the Hartwig Medical Foundation performs diagnostic DNA analyses using whole genome sequencing.
Participating Hospitals
Currently, 37 hospitals are participating in the GENAYA project. This means they can enroll patients who meet the criteria to take part in the study.
More information: www.GENAYA.nl
You read an article in the category Personalized treatment. You may also be interested in GENAYA project, Hartwig Medical Database, Learning healthcare system, Participating hospitals, Research or Whole genome sequencing.All news
Also read
New research shows a more significant role of genetic predisposition in adults with glioblastoma
A recent study published in npj Genomic Medicine shows that hereditary predisposition in adult glioblastoma patients is more common than …
Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This …
New study using Hartwig Medical Foundation data maps how breast cancer’s genetic makeup shifts when it spreads
Analysis of nearly 1,300 tumor genomes across ten genomic subtypes points to candidate drug targets and biomarkers for metastatic breast …
The complete DNA test is an important step toward treating forms of cancer that currently cannot be treated with targeted drugs.